Advanced BioScience Laboratories (ABL) and MicroTest separately reported on the signing of new contract manufacturing agreements. ABL will carry out scale-up and cGMP production of Trophogen’s recombinant human follicle stimulating hormone (rhFSH) analog for Phase I/II clinical studies projected to start in 2014. The rhFSH analog is Trophogen’s lead compound in its superagonist hormone technology platform licensed from the NIH.
Microtest will manufacture and provide supporting pharmaceutical testing services for ImmusanT’s Nexvax2® immunotherapeutic vaccine for a forthcoming trial as a treatment for celiac disease. The candidate has already undergone a Phase I clinical study. ImmusanT recently raised $20 million in financing to progress development of Nexvax2.
Part of the Institut Merieux, ABL is a CRO and manufacturing firm with specialized expertise in therapeutics, vaccines, and other biological products. Its capabilities span basic research, product design, process and assay development, through to preclinical in vivo models, and Phase I/II cGMP biological manufacturing.
Microtest provides a full range of testing services, contract manufacturing, and fill/finish services for the medical device, pharmaceutical, and biotech industries.